Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Referral processes and wait times in primary care.

Neimanis I, Gaebel K, Dickson R, Levy R, Goebel C, Zizzo A, Woods A, Corsini J.

Can Fam Physician. 2017 Aug;63(8):619-624.

2.

Role of family physicians in an urban hospital: Tracking changes between 1977, 1997, and 2014.

Neimanis I, Woods A, Zizzo A, Dickson R, Levy R, Goebel C, Corsini J, Burns S, Gaebel K.

Can Fam Physician. 2017 Mar;63(3):221-227.

3.

DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment [Internet].

Assasi N, Blackhouse G, Campbell K, Gaebel K, Hopkins R, Jegathisawaran J, Sinclair A, Seal K, Kamel C, Levine M, Blackhouse G, Tsoi B, Campbell K, Jegathisawaran J, Weeks L, Garland S, Moulton K, Kaunelis D.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.

4.

Development of Clinical Vignettes to Describe Alzheimer's Disease Health States: A Qualitative Study.

Oremus M, Xie F, Gaebel K.

PLoS One. 2016 Sep 2;11(9):e0162422. doi: 10.1371/journal.pone.0162422. eCollection 2016.

5.

How different are composite and traditional TTO valuations of severe EQ-5D-5L states?

Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA.

Qual Life Res. 2016 Aug;25(8):2101-8. doi: 10.1007/s11136-016-1242-5. Epub 2016 Feb 13.

PMID:
26875190
6.

Can the general public use vignettes to discriminate between Alzheimer's disease health states?

Oremus M, Xie F, Pullenayegum E, Gaebel K.

BMC Geriatr. 2016 Feb 3;16:36. doi: 10.1186/s12877-016-0207-4.

7.

A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.

Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA; Canadian EQ-5D-5L Valuation Study Group.

Med Care. 2016 Jan;54(1):98-105. doi: 10.1097/MLR.0000000000000447.

8.

How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations.

Al Sayah F, Mladenovic A, Gaebel K, Xie F, Johnson JA.

Qual Life Res. 2016 Jan;25(1):35-43. doi: 10.1007/s11136-015-1073-9. Epub 2015 Jul 28.

PMID:
26216584
9.

Committee on Utilization, Review, and Education common referral form.

Neimanis I, Gaebel K, Dickson RC, Levy R, Goebel C, Zizzo AJ, Woods A, Corsini J.

Can Fam Physician. 2014 Oct;60(10):916. No abstract available.

10.

Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?

Pullenayegum EM, Perampaladas K, Gaebel K, Doble B, Xie F.

Eur J Health Econ. 2015 Nov;16(8):847-55. doi: 10.1007/s10198-014-0633-1. Epub 2014 Sep 25. Review.

PMID:
25252970
11.

Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation.

Blackhouse G, Assasi N, Xie F, Gaebel K, Campbell K, Healey JS, O'Reilly D, Goeree R.

Int J Vasc Med. 2013;2013:262809. doi: 10.1155/2013/262809. Epub 2013 Sep 8.

12.

Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best-worst scaling?

Xie F, Pullenayegum E, Gaebel K, Oppe M, Krabbe PF.

Eur J Health Econ. 2014 Apr;15(3):281-8. doi: 10.1007/s10198-013-0474-3. Epub 2013 Apr 4.

PMID:
23553075
13.

Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist.

Xie F, Gaebel K, Perampaladas K, Doble B, Pullenayegum E.

Med Decis Making. 2014 Jan;34(1):8-20. doi: 10.1177/0272989X13480852. Epub 2013 Mar 22. Review.

PMID:
23525701
14.

Self-reported physician adherence to guidelines for measuring blood pressure.

Dickson RC, Gaebel K, Zizzo A, Neimanis I, Bridge M, Corsini J, Goebel C, Levy R, Woods A.

J Am Board Fam Med. 2013 Mar-Apr;26(2):215-7. doi: 10.3122/jabfm.2013.02.120024.

15.

Cost-effectiveness of pharmaceutical management for osteoarthritis pain: a systematic review of the literature and recommendations for future economic evaluation.

Xie F, Tanvejsilp P, Campbell K, Gaebel K.

Drugs Aging. 2013 May;30(5):277-84. doi: 10.1007/s40266-013-0062-3. Review.

PMID:
23420120
16.

Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis.

Assasi N, Xie F, Blackhouse G, Gaebel K, Robertson D, Hopkins R, Healey JS, Goeree R.

J Interv Card Electrophysiol. 2012 Dec;35(3):259-75. doi: 10.1007/s10840-012-9723-0. Epub 2012 Oct 3.

PMID:
23054128
17.

Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses.

Assasi N, Blackhouse G, Xie F, Gaebel K, Robertson D, Hopkins R, Healey J, Roy D, Goeree R.

CADTH Technol Overv. 2012;2(1):e2101. Epub 2012 Mar 1. No abstract available.

18.

Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.

Blackhouse G, Xie F, Levine MA, Campbell K, Assasi N, Gaebel K, O'Reilly D, Tarride J, Goeree R.

J Popul Ther Clin Pharmacol. 2012;19(2):e166-78. Epub 2012 May 1.

PMID:
22580389
19.

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.

Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, Campbell K, Hopkins R, O'Reilly D, Tarride JE, Goeree R.

J Crohns Colitis. 2012 Feb;6(1):77-85. doi: 10.1016/j.crohns.2011.07.007. Epub 2011 Sep 9.

PMID:
22261531
20.

Health economic evaluations help inform payers of the best use of scarce health care resources.

O'Reilly D, Gaebel K, Xie F, Tarride JE, Goeree R.

Int J Circumpolar Health. 2011 Sep;70(4):417-27. Epub 2011 Sep 14.

PMID:
21924008
21.

Measuring health-related quality-of-life for Alzheimer's disease using the general public.

Xie F, Oremus M, Gaebel K.

Qual Life Res. 2012 May;21(4):593-601. doi: 10.1007/s11136-011-9966-8. Epub 2011 Jul 9.

PMID:
21744032
22.

Triple therapy for the management of COPD: a review.

Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, Hernandez P, Goeree R.

COPD. 2011 Jun;8(3):206-43. doi: 10.3109/15412555.2011.560131. Epub 2011 Apr 22. Review.

PMID:
21513437
23.

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.

Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, O'Reilly D, Chalk C, Levine M, Goeree R.

Cost Eff Resour Alloc. 2010 Jun 17;8:14. doi: 10.1186/1478-7547-8-14.

24.

Patient outcomes after anti TNF-alpha drugs for Crohn's disease.

Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):163-75. doi: 10.1586/erp.10.13. Review.

PMID:
20384563
25.

Self-reported use of natural health products: a cross-sectional telephone survey in older Ontarians.

Levine MA, Xu S, Gaebel K, Brazier N, Bédard M, Brazil K, Lohfeld L, MacLeod SM.

Am J Geriatr Pharmacother. 2009 Dec;7(6):383-92. doi: 10.1016/j.amjopharm.2009.12.003.

PMID:
20129259
26.

Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Gaebel K, Blackhouse G, Campbell K, Robertson D, Xie F, Assasi N, Chalk C, Levine M, Goeree R.

Open Med. 2010;4(3):e154-66. Epub 2010 Aug 24.

27.

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis.

Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R.

Cost Eff Resour Alloc. 2009 Dec 11;7:20. doi: 10.1186/1478-7547-7-20.

28.

Integrating family medicine and pharmacy to advance primary care therapeutics.

Dolovich L, Pottie K, Kaczorowski J, Farrell B, Austin Z, Rodriguez C, Gaebel K, Sellors C.

Clin Pharmacol Ther. 2008 Jun;83(6):913-7. doi: 10.1038/clpt.2008.29. Epub 2008 Mar 19. Review.

PMID:
18388882
29.

Automated telephone reminder messages can assist electronic diabetes care.

Mollon B, Holbrook AM, Keshavjee K, Troyan S, Gaebel K, Thabane L, Perera G.

J Telemed Telecare. 2008;14(1):32-6. doi: 10.1258/jtt.2007.070702.

PMID:
18318927
30.

Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care.

Farahani P, Levine M, Gaebel K, LeLorier J, Perrault S, Gillis J, Soon J.

Clin Invest Med. 2007;30(2):E63-9.

PMID:
17716543
31.

Community-based evaluation of etanercept in patients with rheumatoid arthritis.

Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N.

J Rheumatol. 2006 Apr;33(4):665-70. Epub 2006 Mar 1.

PMID:
16568506
32.

Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.

Farahani P, Levine M, Gaebel K, Thabane L.

Can J Clin Pharmacol. 2005 Fall;12(3):e254-63. Epub 2005 Nov 7. Review.

PMID:
16278497
33.

An introductory letter in advance of a telephone survey may increase response rate.

Majowicz SE, Edge VL, Flint J, Sockett P, Doré K, McDougall L, Remple V, Fyfe M, Henson S, Gaebel K.

Can Commun Dis Rep. 2004 Jul 1;30(13):121-3. English, French. No abstract available.

34.

Experience in the development of a postmarketing surveillance network: the pharmacy medication monitoring program.

Willison DJ, Gaebel KA, Borden EK, Levine MA, Poston JW, Goldsmith CH, Wong B.

Ann Pharmacother. 1995 Dec;29(12):1208-13.

PMID:
8672822
35.

Platelets process adsorbed protein: a morphological study.

Gaebel K, Feuerstein IA.

Biomaterials. 1991 Aug;12(6):597-602.

PMID:
1772958

Supplemental Content

Loading ...
Support Center